pulmonary hypertenttion recent PHT.pptx

AhmedElKacer 23 views 14 slides Aug 12, 2024
Slide 1
Slide 1 of 14
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14

About This Presentation

pulmonary hypertension


Slide Content

Pulmonary hypertension made easy Dr / Waseem Omar, MD Lecturer of Cardiology, Al- Azhar University

Definition Mean pulmonary arterial pressure >25 mmHg, or a systolic pulmonary artery pressure of >40 mmHg at rest.

Methods of measurement Invasive: pulmonary artery catheters (i.e. Swan- Ganz catheter). Non invasive: assessment of TR velocity by continuous Doppler by echo (4 X TV2+ RAP).

Mechanisms of Pulmonary Hypertension Hypoxic vasoconstriction: chronic hypoxia causes pulmonary vasoconstriction. causes: COPD, chronic alveolar hypoxia. Decreased area of pulmonary vascular bed: causes: collagen vascular disease, HIV infection, drugs and toxins, thrombotic or embolic disease, inflammatory, interstitial fibrosis, • Volume and pressure overload pulmonary artery pressure will not rise in otherwise normal lung until pulmonary blood flow exceeds 2.5x the basal rate causes: congenital systemic-to-pulmonary shunts (e.g. VSD, ASD, PDA), portopulmonary HTN, left-sided heart conditions,

Classification I: Pulmonary Arterial HTN: Idiopathic Collagen vascular disease (scleroderma, SLE, RA) Congenital systemic-to-pulmonary shunts ( Eisenmenger syndrome) Portopulmonary HTN HIV infection Drugs and toxins (e.g. anorexigens ) Pulmonary veno -occlusive disease Schistosomiasis Sickle cell disease.

II: Pulmonary HTN due to Left Heart Disease Left-sided atrial or ventricular heart disease (e.g. LV dysfunction) Left-sided valvular heart disease (e.g. aortic stenosis, mitral stenosis)

III: Pulmonary HTN due to Lung Disease and/or Hypoxia. Parenchymal lung disease (COPD, interstitial fibrosis, cystic fibrosis) Chronic alveolar hypoxia (chronic high altitude, alveolar hypoventilation disorders, sleep-disordered breathing)

IV: Chronic Thromboembolic Pulmonary HTN (CTEPH) V: Pulmonary HTN with Unclear Multifactorial Mechanisms Hematologic disorders Systemic disorders (e.g. sarcoidosis ) Metabolic disorders Extrinsic compression of central pulmonary veins

Symptoms Symptoms of systemic congestion Dyspnea Fatigue Retrosternal chest pain Syncope Symptoms of underlying disease

Signs Loud, palpable P2 RV heave Right-sided S4 (due to RVH) Systolic murmur (tricuspid regurgitation) If RV failure: right sided S3, increased JVP, positive HJR, peripheral edema ,

Investigations CXR: enlarged central pulmonary arteries and attenuation of peripheral Vs ( bruning ), cardiac changes due to RV enlargement (filling of retrosternal air space). ECG: RVH/right-sided strain. 2-D echo doppler : assessment of right ventricular systolic pressure. Cardiac catheterization: direct measurement of pulmonary artery pressures (necessary to confirm diagnosis). PFTs: for assessmnet of underlying lung disease: CT angiogram: to assess lung parenchyma and possible PE. Serology: ANA positive in 30% of patients with primary pulmonary HTN;

General rules Mild physical activity Routine influenza and pneumococcal vaccine. Digoxin Anticoagulant Avoid high altitude. Oxygen therapy to maintain SO2 ≥ 90%. Diuretics. Contraception as PHT increase mortality by 30-50%.

Specific treatment I: No effective treatment CCBs. prostanoids , Endothelin receptor antagonists, PDE5 inhibitors Lung transplantation